This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Look: Investigating the Phase 2a clinical trial data for PRAX-628 in patients with epilepsy
Ticker(s): PRAXWho's the expert?
Insititution: Duke
- Professor of Neurology at Duke University.
- Currently manages hundreds of OSA patients and is able to discuss the MARIPOSA Phase II clinical trial results.
- Main focus is in epilepsy, sleep disorders, and clinical neurophysiology interpretation.
Interview Goalto discuss the current standard of care and the potential of PRAX-628, a daily oral medication which is currently being developed by Praxis for the treatment of PPR and focal epilepsy.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
